Pharmaceutical markets and insurance worldwide /:
The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government pla...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Bingley, UK :
Emerald/JAI,
2010.
|
| Ausgabe: | 1st ed. |
| Schriftenreihe: | Advances in health economics and health services research ;
v. 22. |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries. |
| Beschreibung: | 1 online resource (xxi, 344 pages) : illustrations. |
| Bibliographie: | Includes bibliographical references. |
| ISBN: | 9781849507172 1849507171 9781849507165 1849507163 |
| ISSN: | 0731-2199 ; |
Internformat
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBU-ocn649478955 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 100721s2010 enka ob 000 0 eng d | ||
| 040 | |a N$T |b eng |e pn |c N$T |d IDEBK |d OCLCQ |d CDX |d E7B |d OCLCQ |d UWO |d OCLCQ |d BWS |d OCLCO |d OCLCF |d NLGGC |d OCLCO |d BEDGE |d OCLCQ |d SUF |d AGLDB |d KIJ |d OCLCO |d JBG |d OCLCO |d OCLCQ |d VTS |d OCLCA |d REC |d OCLCO |d OCLCA |d S9I |d STF |d M8D |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d OCLCL |d OCLCQ | ||
| 019 | |a 651129060 |a 738739347 |a 823930033 |a 964597717 |a 1167148570 | ||
| 020 | |a 9781849507172 |q (electronic bk.) | ||
| 020 | |a 1849507171 |q (electronic bk.) | ||
| 020 | |a 9781849507165 |q (hbk.) | ||
| 020 | |a 1849507163 |q (hbk.) | ||
| 024 | 8 | |a 9786612526329 | |
| 035 | |a (OCoLC)649478955 |z (OCoLC)651129060 |z (OCoLC)738739347 |z (OCoLC)823930033 |z (OCoLC)964597717 |z (OCoLC)1167148570 | ||
| 037 | |a 252632 |b MIL | ||
| 050 | 4 | |a HD9665.5 |b .P53 2010eb | |
| 060 | 4 | |a W1 |b AD621T v.22 2010 | |
| 060 | 4 | |a QV 736 | |
| 072 | 7 | |a BUS |x 070080 |2 bisacsh | |
| 080 | |a 615 | ||
| 082 | 7 | |a 338.47615 |2 22 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Pharmaceutical markets and insurance worldwide / |c edited by Avi Dor. |
| 250 | |a 1st ed. | ||
| 260 | |a Bingley, UK : |b Emerald/JAI, |c 2010. | ||
| 300 | |a 1 online resource (xxi, 344 pages) : |b illustrations. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a data file |2 rda | ||
| 490 | 1 | |a Advances in health economics and health services research, |x 0731-2199 ; |v v. 22 | |
| 504 | |a Includes bibliographical references. | ||
| 505 | 0 | 0 | |g Part I: International reviews -- |t Pharmaceutical policies in European countries / |r Pedro Pita Barros -- |t International experience with comparative effectiveness research : case studies from England/Wales and Germany / |r John F.P. Bridges [and others] -- |g Part II: National case studies -- |t Pharmaceutical policy in the Netherlands : from price regulation towards managed competition / |r Lieke H.H.M. Boonen [and others] -- |t Impact of pharmaceutical regulation and policies on health system performance goals in israel / |r Philip Sax and Amir Shmueli -- |t Global budgets and provider incentives : hospitals' drug expenditures in Taiwan / |r Shin-Yi Chou [and others] -- |t Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries / |r Jack Hoadley and Kosali Simon -- |g Part III: U.S. studies : from markets to policy innovations -- |t Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes / |r William E. Encinosa, Didem Bernard and Avi Dor -- |t Cost shring, benefit design, and adherence : the case of multiple sclerosis / |r Avi Dor [and others] -- |t Generic utilization and cost-sharing for prescription drugs / |r Teresa Bernard Gibson, Catherine G. McLaughlin and Dean G. Smith -- |t Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? / |r Jie Chen and John A. Rizzo -- |t Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / |r Yuriy Pylypchuk -- |t The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program / |r Frank R. Lichtenberg -- |g Part IV: Special topics -- |t Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / |r Yang Xie [and others] -- |t Patents, innovation, and the welfare effects of Medicare Part D / |r Adam Gailey, Darius Lakdawalla and Neeraj Sood. |
| 588 | 0 | |a Print version record. | |
| 520 | |a The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries. | ||
| 650 | 0 | |a Pharmaceutical industry |x Economic aspects. | |
| 650 | 0 | |a Medical economics. |0 http://id.loc.gov/authorities/subjects/sh85082915 | |
| 650 | 0 | |a Health insurance |x Finance. |0 http://id.loc.gov/authorities/subjects/sh85066936 | |
| 650 | 0 | |a Health insurance |x Costs. | |
| 650 | 2 | |a Drug Industry |x economics |0 https://id.nlm.nih.gov/mesh/D004345Q000191 | |
| 650 | 2 | |a Economics, Medical |0 https://id.nlm.nih.gov/mesh/D004470 | |
| 650 | 2 | |a Insurance, Health |x economics |0 https://id.nlm.nih.gov/mesh/D007348Q000191 | |
| 650 | 6 | |a Industrie pharmaceutique |x Aspect économique. | |
| 650 | 6 | |a Économie de la santé. | |
| 650 | 7 | |a Health economics. |2 bicssc | |
| 650 | 7 | |a BUSINESS & ECONOMICS |x Industries |x Service. |2 bisacsh | |
| 650 | 7 | |a Gestion d'entreprises. |2 eclas | |
| 650 | 7 | |a Health insurance |x Costs |2 fast | |
| 650 | 7 | |a Health insurance |x Finance |2 fast | |
| 650 | 7 | |a Medical economics |2 fast | |
| 650 | 7 | |a Pharmaceutical industry |x Economic aspects |2 fast | |
| 700 | 1 | |a Dor, Avi, |d 1956- |0 http://id.loc.gov/authorities/names/n88064019 | |
| 776 | 0 | 8 | |i Print version: |t Pharmaceutical markets and insurance worldwide. |b 1st ed. |d Bingley, UK : Emerald/JAI, 2010 |z 9781849507165 |w (OCoLC)502423752 |
| 830 | 0 | |a Advances in health economics and health services research ; |v v. 22. |0 http://id.loc.gov/authorities/names/no2006020946 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBU |q FWS_PDA_EBU |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=318261 |3 Volltext |
| 938 | |a Coutts Information Services |b COUT |n 12899435 | ||
| 938 | |a ebrary |b EBRY |n ebr10381745 | ||
| 938 | |a EBSCOhost |b EBSC |n 318261 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBU | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBU-ocn649478955 |
|---|---|
| _version_ | 1816796899476242432 |
| adam_text | |
| any_adam_object | |
| author2 | Dor, Avi, 1956- |
| author2_role | |
| author2_variant | a d ad |
| author_GND | http://id.loc.gov/authorities/names/n88064019 |
| author_additional | Pedro Pita Barros -- John F.P. Bridges [and others] -- Lieke H.H.M. Boonen [and others] -- Philip Sax and Amir Shmueli -- Shin-Yi Chou [and others] -- Jack Hoadley and Kosali Simon -- William E. Encinosa, Didem Bernard and Avi Dor -- Avi Dor [and others] -- Teresa Bernard Gibson, Catherine G. McLaughlin and Dean G. Smith -- Jie Chen and John A. Rizzo -- Yuriy Pylypchuk -- Frank R. Lichtenberg -- Yang Xie [and others] -- Adam Gailey, Darius Lakdawalla and Neeraj Sood. |
| author_facet | Dor, Avi, 1956- |
| author_sort | Dor, Avi, 1956- |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | H - Social Science |
| callnumber-label | HD9665 |
| callnumber-raw | HD9665.5 .P53 2010eb |
| callnumber-search | HD9665.5 .P53 2010eb |
| callnumber-sort | HD 49665.5 P53 42010EB |
| callnumber-subject | HD - Industries, Land Use, Labor |
| collection | ZDB-4-EBU |
| contents | Pharmaceutical policies in European countries / International experience with comparative effectiveness research : case studies from England/Wales and Germany / Pharmaceutical policy in the Netherlands : from price regulation towards managed competition / Impact of pharmaceutical regulation and policies on health system performance goals in israel / Global budgets and provider incentives : hospitals' drug expenditures in Taiwan / Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries / Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes / Cost shring, benefit design, and adherence : the case of multiple sclerosis / Generic utilization and cost-sharing for prescription drugs / Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? / Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program / Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Patents, innovation, and the welfare effects of Medicare Part D / |
| ctrlnum | (OCoLC)649478955 |
| dewey-full | 338.47615 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.47615 |
| dewey-search | 338.47615 |
| dewey-sort | 3338.47615 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| edition | 1st ed. |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05989cam a2200733 a 4500</leader><controlfield tag="001">ZDB-4-EBU-ocn649478955</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">100721s2010 enka ob 000 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">IDEBK</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">CDX</subfield><subfield code="d">E7B</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">UWO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">BWS</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCF</subfield><subfield code="d">NLGGC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">BEDGE</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">SUF</subfield><subfield code="d">AGLDB</subfield><subfield code="d">KIJ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">JBG</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VTS</subfield><subfield code="d">OCLCA</subfield><subfield code="d">REC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">S9I</subfield><subfield code="d">STF</subfield><subfield code="d">M8D</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCL</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">651129060</subfield><subfield code="a">738739347</subfield><subfield code="a">823930033</subfield><subfield code="a">964597717</subfield><subfield code="a">1167148570</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781849507172</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1849507171</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781849507165</subfield><subfield code="q">(hbk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1849507163</subfield><subfield code="q">(hbk.)</subfield></datafield><datafield tag="024" ind1="8" ind2=" "><subfield code="a">9786612526329</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)649478955</subfield><subfield code="z">(OCoLC)651129060</subfield><subfield code="z">(OCoLC)738739347</subfield><subfield code="z">(OCoLC)823930033</subfield><subfield code="z">(OCoLC)964597717</subfield><subfield code="z">(OCoLC)1167148570</subfield></datafield><datafield tag="037" ind1=" " ind2=" "><subfield code="a">252632</subfield><subfield code="b">MIL</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">HD9665.5</subfield><subfield code="b">.P53 2010eb</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">W1</subfield><subfield code="b">AD621T v.22 2010</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QV 736</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">BUS</subfield><subfield code="x">070080</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="080" ind1=" " ind2=" "><subfield code="a">615</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">338.47615</subfield><subfield code="2">22</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Pharmaceutical markets and insurance worldwide /</subfield><subfield code="c">edited by Avi Dor.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Bingley, UK :</subfield><subfield code="b">Emerald/JAI,</subfield><subfield code="c">2010.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xxi, 344 pages) :</subfield><subfield code="b">illustrations.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">data file</subfield><subfield code="2">rda</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Advances in health economics and health services research,</subfield><subfield code="x">0731-2199 ;</subfield><subfield code="v">v. 22</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="505" ind1="0" ind2="0"><subfield code="g">Part I: International reviews --</subfield><subfield code="t">Pharmaceutical policies in European countries /</subfield><subfield code="r">Pedro Pita Barros --</subfield><subfield code="t">International experience with comparative effectiveness research : case studies from England/Wales and Germany /</subfield><subfield code="r">John F.P. Bridges [and others] --</subfield><subfield code="g">Part II: National case studies --</subfield><subfield code="t">Pharmaceutical policy in the Netherlands : from price regulation towards managed competition /</subfield><subfield code="r">Lieke H.H.M. Boonen [and others] --</subfield><subfield code="t">Impact of pharmaceutical regulation and policies on health system performance goals in israel /</subfield><subfield code="r">Philip Sax and Amir Shmueli --</subfield><subfield code="t">Global budgets and provider incentives : hospitals' drug expenditures in Taiwan /</subfield><subfield code="r">Shin-Yi Chou [and others] --</subfield><subfield code="t">Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries /</subfield><subfield code="r">Jack Hoadley and Kosali Simon --</subfield><subfield code="g">Part III: U.S. studies : from markets to policy innovations --</subfield><subfield code="t">Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes /</subfield><subfield code="r">William E. Encinosa, Didem Bernard and Avi Dor --</subfield><subfield code="t">Cost shring, benefit design, and adherence : the case of multiple sclerosis /</subfield><subfield code="r">Avi Dor [and others] --</subfield><subfield code="t">Generic utilization and cost-sharing for prescription drugs /</subfield><subfield code="r">Teresa Bernard Gibson, Catherine G. McLaughlin and Dean G. Smith --</subfield><subfield code="t">Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? /</subfield><subfield code="r">Jie Chen and John A. Rizzo --</subfield><subfield code="t">Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions /</subfield><subfield code="r">Yuriy Pylypchuk --</subfield><subfield code="t">The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program /</subfield><subfield code="r">Frank R. Lichtenberg --</subfield><subfield code="g">Part IV: Special topics --</subfield><subfield code="t">Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era /</subfield><subfield code="r">Yang Xie [and others] --</subfield><subfield code="t">Patents, innovation, and the welfare effects of Medicare Part D /</subfield><subfield code="r">Adam Gailey, Darius Lakdawalla and Neeraj Sood.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Economic aspects.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medical economics.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85082915</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Health insurance</subfield><subfield code="x">Finance.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85066936</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Health insurance</subfield><subfield code="x">Costs.</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Drug Industry</subfield><subfield code="x">economics</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D004345Q000191</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Economics, Medical</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D004470</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Insurance, Health</subfield><subfield code="x">economics</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D007348Q000191</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Industrie pharmaceutique</subfield><subfield code="x">Aspect économique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Économie de la santé.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Health economics.</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BUSINESS & ECONOMICS</subfield><subfield code="x">Industries</subfield><subfield code="x">Service.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gestion d'entreprises.</subfield><subfield code="2">eclas</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Health insurance</subfield><subfield code="x">Costs</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Health insurance</subfield><subfield code="x">Finance</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medical economics</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Economic aspects</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dor, Avi,</subfield><subfield code="d">1956-</subfield><subfield code="0">http://id.loc.gov/authorities/names/n88064019</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Pharmaceutical markets and insurance worldwide.</subfield><subfield code="b">1st ed.</subfield><subfield code="d">Bingley, UK : Emerald/JAI, 2010</subfield><subfield code="z">9781849507165</subfield><subfield code="w">(OCoLC)502423752</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Advances in health economics and health services research ;</subfield><subfield code="v">v. 22.</subfield><subfield code="0">http://id.loc.gov/authorities/names/no2006020946</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBU</subfield><subfield code="q">FWS_PDA_EBU</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=318261</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Coutts Information Services</subfield><subfield code="b">COUT</subfield><subfield code="n">12899435</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10381745</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">318261</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBU</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBU-ocn649478955 |
| illustrated | Illustrated |
| indexdate | 2024-11-26T14:49:01Z |
| institution | BVB |
| isbn | 9781849507172 1849507171 9781849507165 1849507163 |
| issn | 0731-2199 ; |
| language | English |
| oclc_num | 649478955 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (xxi, 344 pages) : illustrations. |
| psigel | ZDB-4-EBU |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Emerald/JAI, |
| record_format | marc |
| series | Advances in health economics and health services research ; |
| series2 | Advances in health economics and health services research, |
| spelling | Pharmaceutical markets and insurance worldwide / edited by Avi Dor. 1st ed. Bingley, UK : Emerald/JAI, 2010. 1 online resource (xxi, 344 pages) : illustrations. text txt rdacontent computer c rdamedia online resource cr rdacarrier data file rda Advances in health economics and health services research, 0731-2199 ; v. 22 Includes bibliographical references. Part I: International reviews -- Pharmaceutical policies in European countries / Pedro Pita Barros -- International experience with comparative effectiveness research : case studies from England/Wales and Germany / John F.P. Bridges [and others] -- Part II: National case studies -- Pharmaceutical policy in the Netherlands : from price regulation towards managed competition / Lieke H.H.M. Boonen [and others] -- Impact of pharmaceutical regulation and policies on health system performance goals in israel / Philip Sax and Amir Shmueli -- Global budgets and provider incentives : hospitals' drug expenditures in Taiwan / Shin-Yi Chou [and others] -- Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries / Jack Hoadley and Kosali Simon -- Part III: U.S. studies : from markets to policy innovations -- Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes / William E. Encinosa, Didem Bernard and Avi Dor -- Cost shring, benefit design, and adherence : the case of multiple sclerosis / Avi Dor [and others] -- Generic utilization and cost-sharing for prescription drugs / Teresa Bernard Gibson, Catherine G. McLaughlin and Dean G. Smith -- Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? / Jie Chen and John A. Rizzo -- Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / Yuriy Pylypchuk -- The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program / Frank R. Lichtenberg -- Part IV: Special topics -- Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Yang Xie [and others] -- Patents, innovation, and the welfare effects of Medicare Part D / Adam Gailey, Darius Lakdawalla and Neeraj Sood. Print version record. The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries. Pharmaceutical industry Economic aspects. Medical economics. http://id.loc.gov/authorities/subjects/sh85082915 Health insurance Finance. http://id.loc.gov/authorities/subjects/sh85066936 Health insurance Costs. Drug Industry economics https://id.nlm.nih.gov/mesh/D004345Q000191 Economics, Medical https://id.nlm.nih.gov/mesh/D004470 Insurance, Health economics https://id.nlm.nih.gov/mesh/D007348Q000191 Industrie pharmaceutique Aspect économique. Économie de la santé. Health economics. bicssc BUSINESS & ECONOMICS Industries Service. bisacsh Gestion d'entreprises. eclas Health insurance Costs fast Health insurance Finance fast Medical economics fast Pharmaceutical industry Economic aspects fast Dor, Avi, 1956- http://id.loc.gov/authorities/names/n88064019 Print version: Pharmaceutical markets and insurance worldwide. 1st ed. Bingley, UK : Emerald/JAI, 2010 9781849507165 (OCoLC)502423752 Advances in health economics and health services research ; v. 22. http://id.loc.gov/authorities/names/no2006020946 FWS01 ZDB-4-EBU FWS_PDA_EBU https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=318261 Volltext |
| spellingShingle | Pharmaceutical markets and insurance worldwide / Advances in health economics and health services research ; Pharmaceutical policies in European countries / International experience with comparative effectiveness research : case studies from England/Wales and Germany / Pharmaceutical policy in the Netherlands : from price regulation towards managed competition / Impact of pharmaceutical regulation and policies on health system performance goals in israel / Global budgets and provider incentives : hospitals' drug expenditures in Taiwan / Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries / Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes / Cost shring, benefit design, and adherence : the case of multiple sclerosis / Generic utilization and cost-sharing for prescription drugs / Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? / Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program / Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Patents, innovation, and the welfare effects of Medicare Part D / Pharmaceutical industry Economic aspects. Medical economics. http://id.loc.gov/authorities/subjects/sh85082915 Health insurance Finance. http://id.loc.gov/authorities/subjects/sh85066936 Health insurance Costs. Drug Industry economics https://id.nlm.nih.gov/mesh/D004345Q000191 Economics, Medical https://id.nlm.nih.gov/mesh/D004470 Insurance, Health economics https://id.nlm.nih.gov/mesh/D007348Q000191 Industrie pharmaceutique Aspect économique. Économie de la santé. Health economics. bicssc BUSINESS & ECONOMICS Industries Service. bisacsh Gestion d'entreprises. eclas Health insurance Costs fast Health insurance Finance fast Medical economics fast Pharmaceutical industry Economic aspects fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85082915 http://id.loc.gov/authorities/subjects/sh85066936 https://id.nlm.nih.gov/mesh/D004345Q000191 https://id.nlm.nih.gov/mesh/D004470 https://id.nlm.nih.gov/mesh/D007348Q000191 |
| title | Pharmaceutical markets and insurance worldwide / |
| title_alt | Pharmaceutical policies in European countries / International experience with comparative effectiveness research : case studies from England/Wales and Germany / Pharmaceutical policy in the Netherlands : from price regulation towards managed competition / Impact of pharmaceutical regulation and policies on health system performance goals in israel / Global budgets and provider incentives : hospitals' drug expenditures in Taiwan / Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries / Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes / Cost shring, benefit design, and adherence : the case of multiple sclerosis / Generic utilization and cost-sharing for prescription drugs / Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? / Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program / Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Patents, innovation, and the welfare effects of Medicare Part D / |
| title_auth | Pharmaceutical markets and insurance worldwide / |
| title_exact_search | Pharmaceutical markets and insurance worldwide / |
| title_full | Pharmaceutical markets and insurance worldwide / edited by Avi Dor. |
| title_fullStr | Pharmaceutical markets and insurance worldwide / edited by Avi Dor. |
| title_full_unstemmed | Pharmaceutical markets and insurance worldwide / edited by Avi Dor. |
| title_short | Pharmaceutical markets and insurance worldwide / |
| title_sort | pharmaceutical markets and insurance worldwide |
| topic | Pharmaceutical industry Economic aspects. Medical economics. http://id.loc.gov/authorities/subjects/sh85082915 Health insurance Finance. http://id.loc.gov/authorities/subjects/sh85066936 Health insurance Costs. Drug Industry economics https://id.nlm.nih.gov/mesh/D004345Q000191 Economics, Medical https://id.nlm.nih.gov/mesh/D004470 Insurance, Health economics https://id.nlm.nih.gov/mesh/D007348Q000191 Industrie pharmaceutique Aspect économique. Économie de la santé. Health economics. bicssc BUSINESS & ECONOMICS Industries Service. bisacsh Gestion d'entreprises. eclas Health insurance Costs fast Health insurance Finance fast Medical economics fast Pharmaceutical industry Economic aspects fast |
| topic_facet | Pharmaceutical industry Economic aspects. Medical economics. Health insurance Finance. Health insurance Costs. Drug Industry economics Economics, Medical Insurance, Health economics Industrie pharmaceutique Aspect économique. Économie de la santé. Health economics. BUSINESS & ECONOMICS Industries Service. Gestion d'entreprises. Health insurance Costs Health insurance Finance Medical economics Pharmaceutical industry Economic aspects |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=318261 |
| work_keys_str_mv | AT doravi pharmaceuticalmarketsandinsuranceworldwide |